利妥昔单抗在间质性肺病中的使用进展

杨天芸 ,  陈智鸿

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (10) : 1392 -1399.

PDF (569KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (10) : 1392 -1399. DOI: 10.12092/j.issn.1009-2501.2026.10.010
综述与讲座

利妥昔单抗在间质性肺病中的使用进展

作者信息 +

Progress in the use of rituximab in interstitial lung disease

Author information +
文章历史 +
PDF (581K)

摘要

间质性肺病(interstitial lung disease,ILD)作为结缔组织病(connective tissue diseases, CTD)较为严重的肺部并发症,传统药物治疗疗效欠佳。近年来,生物制剂等治疗方式的运用,改善了此类患者的预后状况。利妥昔单抗(rituximab,RTX)是特异性针对 B 淋巴细胞表面 CD20 抗原的人鼠嵌合单克隆抗体。临床实践显示,RTX 可作为糖皮质激素及免疫抑制治疗失败的多种结缔组织相关性间质性肺病(connective tissue dis-ease-related interstitial lung disease, CTD-ILD)患者有价值的治疗选择。本文对 RTX 的作用机制及其在 CTD-ILD 中的应用进行综述。

Abstract

Interstitial lung disease (ILD) represents a severe pulmonary complication of connective tissue diseases (CTD), and conventional pharmacotherapy yields unsatisfactory therapeutic outcomes. In recent years, the application of therapeutic approaches such as biologics has improved the prognosis of such patients. Rituximab (RTX) is a chimeric human-mouse monoclonal antibody specifically targeting the CD20 antigen on the surface of B lymphocytes. Clinical practice has demonstrated that RTX serves as a valuable therapeutic option for patients with various connective tissue disease-related interstitial lung disease (CTD-ILD) who fail glucocorticoid and immunosuppressive therapy. This article reviews the mechanism of action of RTX and its application in connective tissue disease-associated ILD.

关键词

利妥昔单抗 / 间质性肺病 / 生物制剂 / 结缔组织病

Key words

rituximab / interstitial lung disease / biologic agents / connective tissue diseases

引用本文

引用格式 ▾
杨天芸,陈智鸿. 利妥昔单抗在间质性肺病中的使用进展[J]. 中国临床药理学与治疗学, 2026, 31(10): 1392-1399 DOI:10.12092/j.issn.1009-2501.2026.10.010

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Liu Y, Liu Y, Xu J, et al. Efficacy of rituximab versus cyclophosphamide in connective tissue disease-related interstitial lung disease: a systematic review and meta-analysis[J].Clin Rheumatol, 2025, 44(7): 2601-2610.

[2]

Robles-Perez A, Molina-Molina M.Treatment considerations of lung involvement in rheumatologic disease[J].Respiration, 2015, 90(4): 265-274.

[3]

邢楠舒, 张榕. 生物制剂及小分子靶向药物治疗 CTD-ILD[J].中华临床免疫和变态反应杂志, 2020, 14(5): 495-499.

[4]

Weiner GJ. Rituximab: mechanism of action[J].Semin Hematol, 2010, 47(2): 115-123.

[5]

Liossis SC, Bounia CA.Treating autoimmune-related interstitial lung disease with B cell depletion[J].Front Med (Lausanne), 2022, 9: 937561.

[6]

Van Meerten T, Hagenbeek A. CD20-targeted therapy: the next generation of antibodies[J].Semin Hematol, 2010, 47(2): 199-210.

[7]

霍荣秀, 郭乾育, 许珂. 药物治疗结缔组织病相关间质性肺疾病的进展[J].中华风湿病学杂志, 2022, 26(7): 489-493.

[8]

Thong L, Chawke LJ, Murphy G, et al. Management of myositis associated interstitial lung disease[J].Rheumatol Int, 2023, 43(7): 1209-1220.

[9]

Hallowell RW, Danoff SK.Diagnosis and management of myositis-associated lung disease[J].Chest, 2023, 163(6): 1476-1491.

[10]

Marie I, Hatron PY, Dominique S, et al. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients[J].Arthritis Rheum, 2011, 63(11): 3439-3447.

[11]

Marie I, Josse S, Hatron PY, et al. Interstitial lung disease in anti-Jo1 patients with antisynthetase syndrome[J].Arthritis Care Res (Hoboken), 2013, 65(5): 800-808.

[12]

Yu KH, Wu YJ, Kuo CF, et al. Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases[J].Clin Rheumatol, 2011, 30(12): 1595-1601.

[13]

Sugiyama Y, Yoshimi R, Tamura M, et al. The predictive prognostic factors for polymyositis/dermatomyositis-associated interstitial lung disease[J].Arthritis Res Ther, 2018, 20(1): 7.

[14]

Narváez J, Cañadillas E, Castellví I, et al. Rituximab in the treatment of progressive interstitial lung disease associated with the antisynthetase syndrome[J].Arthritis Res Ther, 2024, 26(1): 122.

[15]

Maher TM, Tudor VA, Saunders P, et al. RECITAL Investigators. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial[J].Lancet Respir Med, 2023, 11(1): 45-54.

[16]

Kouranloo K, Dey M, Elwell H, et al. Management and outcomes of interstitial lung disease associated with anti-synthetase syndrome: a systematic literature review[J].Rheumatology (Oxford), 2025, 64(1): 45-55.

[17]

Fujikawa K, Kawakami A, Kaji K, et al. Association of distinct clinical subsets with myositis-specific autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a single-centre, cross-sectional study[J].Scand J Rheumatol, 2009, 38(4): 263-267.

[18]

He C, Li W, Xie Q, et al. Rituximab in the treatment of interstitial lung diseases related to anti-melanoma differentiation-associated gene 5 dermatomyositis: a systematic review[J].Front Immunol, 2022, 12: 820163.

[19]

Nascimento J, Tenazinha C, Campanilho-Marques R, et al. Rituximab in the treatment of anti-MDA-5 dermatomyositis-associated interstitial lung disease: a case-based literature review[J].ARP Rheumatol, 2022, 1(2): 168-173.

[20]

Dai Y, Wang W, Yu Y, et al. Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology, pathogenesis and management[J].Clin Rheumatol, 2021, 40(4): 1211-1220.

[21]

Atkins SR, Turesson C, Myers JL, et al. Morphologic and quantitative assessment of CD20+ B cell infiltrates in rheumatoid arthritis-associated nonspecific interstitial pneumonia and usual interstitial pneumonia[J].Arthritis Rheum, 2006, 54(2): 635-641.

[22]

Md Yusof MY, Kabia A, Darby M, et al. Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre[J].Rheumatology (Oxford), 2017, 56(8): 1348-1357.

[23]

Fui A, Bergantini L, Selvi E, et al. Rituximab therapy in interstitial lung disease associated with rheumatoid arthritis[J].Intern Med J, 2020, 50(3): 330-336.

[24]

Pugashetti JV, Lee JS. Overview of rheumatoid arthritis-associated interstitial lung disease and its treatment[J].Semin Respir Crit Care Med, 2024, 45(3): 329-341.

[25]

Kelly CA, Nisar M, Arthanari S, et al. Rheumatoid arthritis related interstitial lung disease-improving outcomes over 25 years: a large multicentre UK study[J].Rheumatology (Oxford), 2021, 60(4): 1882-1890.

[26]

Holroyd CR, Seth R, Bukhari M, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis-Executive summary[J].Rheumatology (Oxford), 2019, 58(2): 220-226.

[27]

Fassio A, Sebastiani M, Pollastri F, et al. Updated systematic literature review and meta-analysis to inform the Italian Society of Rheumatology recommendations on the treatment of rheumatoid arthritis-associated interstitial lung disease[J].Autoimmun Rev, 2025, 24(12): 103922.

[28]

Volkmann ER, Andréasson K, Smith V.Systemic sclerosis[J].Lancet, 2023, 401(10373): 304-318.

[29]

Sircar G, Goswami RP, Sircar D, et al. Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial[J].Rheumatology (Oxford), 2018, 57(12): 2106-2113.

[30]

Ebata S, Yoshizaki A, Oba K, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial[J].Lancet Rheumatol, 2021, 3(7): e489-e497.

[31]

中国初级卫生保健基金会风湿免疫学分会干燥综合征和 IgG4 相关性疾病专委会, 系统性红斑狼疮专委会. 利妥昔单抗治疗风湿免疫病中国专家共识 (2024 版)[J].中华风湿病学杂志, 2024, 28(8): 521-537.

[32]

Negrini S, Emmi G, Greco M, et al. Sjögren's syndrome: a systemic autoimmune disease[J].Clin Exp Med, 2022, 22(1): 9-25.

[33]

Pontarini E, Sciacca E, Chowdhury F, et al. Serum and tissue biomarkers associated with composite of relevant endpoints for Sjögren syndrome (CRESS) and Sjögren tool for assessing response (STAR) to B cell-targeted therapy in the trial of anti-B cell therapy in patients with primary Sjögren syndrome (TRACTISS)[J].Arthritis Rheumatol, 2024, 76(5): 763-776.

[34]

Manfredi A, Sebastiani M, Cerri S, et al. Prevalence and characterization of non-sicca onset primary Sjögren syndrome with interstitial lung involvement[J].Clin Rheumatol, 2017, 36(6): 1261-1268.

[35]

Lin W, Xin Z, Zhang J, et al. Interstitial lung disease in primary Sjögren's syndrome[J].BMC Pulm Med, 2022, 22(1): 73.

[36]

Vacchi C, Sebastiani M, Cassone G, et al. Therapeutic options for the treatment of interstitial lung disease related to connective tissue diseases. a narrative review[J].J Clin Med, 2020, 9(2): 407.

[37]

Ramos-Casals M, Brito-Zerón P, Sisó-Almirall A, et al. Topical and systemic medications for the treatment of primary Sjögren's syndrome[J].Nat Rev Rheumatol, 2012, 8(7): 399-411.

[38]

Saraux A, Pers JO, Devauchelle-Pensec V. Treatment of primary Sjögren syndrome[J].Nat Rev Rheumatol, 2016, 12(8): 456-471.

[39]

Verstappen GM, Van Nimwegen JF, Vissink A, et al. The value of rituximab treatment in primary Sjögren's syndrome[J].Clin Immunol, 2017, 182: 62-71.

[40]

Chen MH, Chen CK, Chou HP, et al. Rituximab therapy in primary Sjögren's syndrome with interstitial lung disease: a retrospective cohort study[J].Clin Exp Rheumatol, 2016, 34(6): 1077-1084.

[41]

Gupta S, Ferrada MA, Hasni SA.Pulmonary manifestations of primary Sjögren's syndrome: underlying immunological mechanisms, clinical presentation, and management[J].Front Immunol, 2019, 10: 1327.

[42]

Price EJ, Rauz S, Tappuni AR, et al. The british society for rheumatology guideline for the management of adults with primary Sjögren's syndrome[J].Rheumatology (Oxford), 2017, 56(10): e24-e48.

[43]

Reina D, Roig Vilaseca D, Torrente-Segarra V, et al. Sjögren's syndrome-associated interstitial lung disease: a multicenter study[J].Reumatol Clin, 2016, 12(4): 201-205.

[44]

Enomoto Y, Takemura T, Hagiwara E, et al. Prognostic factors in interstitial lung disease associated with primary Sjögren's syndrome: a retrospective analysis of 33 pathologically-proven cases[J].PLoS One, 2013, 8(9): e73774.

[45]

Amarnani R, Yeoh SA, Denneny EK, et al. Lupus and the lungs: the assessment and management of pulmonary manifestations of systemic lupus erythematosus[J].Front Med (Lausanne), 2021, 7: 610257.

[46]

Benham H, Garske L, Vecchio P, et al. Successful treatment of shrinking lung syndrome with rituximab in a patient with systemic lupus erythematosus[J].J Clin Rheumatol, 2010, 16(2): 68-70.

[47]

Langenskiöld E, Bonetti A, Fitting JW, et al. Shrinking lung syndrome successfully treated with rituximab and cyclophosphamide[J].Respiration, 2012, 84(2): 144-149.

[48]

Arulkumaran N, Periselneris N, Gaskin G, et al. Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study[J].Rheumatology (Oxford), 2011, 50(11): 2035-2043.

[49]

Comarmond C, Crestani B, Tazi A, et al. Pulmonary fibrosis in antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis: a series of 49 patients and review of the literature[J].Medicine (Baltimore), 2014, 93(24): 340-349.

[50]

Sebastiani M, Manfredi A, Vacchi C, et al. Epidemiology and management of interstitial lung disease in ANCA-associated vasculitis[J].Clin Exp Rheumatol, 2020, 124(2): 221-231.

[51]

Hozumi H, Enomoto N, Oyama Y, et al. Clinical implication of proteinase-3-antineutrophil cytoplasmic antibody in patients with idiopathic interstitial pneumonias[J].Lung, 2016, 194(2): 235-242.

[52]

Fernandez Casares M, Gonzalez A, Fielli M, et al. Microscopic polyangiitis associated with pulmonary fibrosis[J].Clin Rheumatol, 2015, 34(7): 1273-1277.

[53]

Streho M, Sable-Fourtassou R, Brion MC, et al. Churg-strauss syndrome and pulmonary fibrosis: an unusual association[J].Presse Med, 2006, 35(9 Pt 1): 1259-1262.

[54]

Maillet T, Goletto T, Beltramo G, et al. French Vasculitis Study Group (FVSG). Usual interstitial pneumonia in ANCA-associated vasculitis: a poor prognostic factor[J].J Autoimmun, 2020, 106: 102338.

[55]

Yates M, Watts RA, Bajema IM, et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis[J].Ann Rheum Dis, 2016, 75(9): 1583-1594.

[56]

Morisset J, Lee JS.New trajectories in the treatment of interstitial lung disease: treat the disease or treat the underlying pattern[J].Curr Opin Pulm Med, 2019, 25(5): 442-449.

[57]

Robles-Perez A, Dorca J, Castellví I, et al. Rituximab effect in severe progressive connective tissue disease-related lung disease: preliminary data[J].Rheumatol Int, 2020, 40(5): 719-726.

[58]

Barba T, Mainbourg S, Nasser M, et al. Lung diseases in inflammatory myopathies[J].Semin Respir Crit Care Med, 2019, 40(2): 255-270.

[59]

Romero-Bueno F, Diaz Del Campo P, Trallero-Araguás E, et al. MEDRA5 (Spanish MDA-5 Register) group. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease[J].Semin Arthritis Rheum, 2020, 50(4): 776-790.

[60]

Tony HP, Burmester G, Schulze-Koops H, et al. GRAID investigators. Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)[J].Arthritis Res Ther, 2011, 13(3): R75.

[61]

Kerschbaumer A, Sepriano A, Bergstra SA, et al. Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis[J].Ann Rheum Dis, 2023, 82(1): 95-106.

[62]

Kari JA, El-Morshedy SM, El-Desoky S, et al. Rituximab for refractory cases of childhood nephrotic syndrome[J].Pediatr Nephrol, 2011, 26(5): 733-737.

[63]

Chari R, Abdelghany Y, Purcell M, et al. Rituximab induced lung injury[J].BMC Pulm Med, 2025, 25(1): 359.

[64]

Liu X, Hong XN, Gu YJ, et al. Interstitial pneumonitis during rituximab-containing chemotherapy for non-Hodgkin lymphoma[J].Leuk Lymphoma, 2008, 49(9): 1778-1783.

[65]

Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease[J].Am J Hematol, 2007, 82(10): 916-919.

[66]

Zamfir AS, Marinca MV, Zamfir CL, et al. Rituximab-induced interstitial lung disease: a possible underestimated complication-a systematic review[J].Cancers (Basel), 2025, 17(23): 3786.

[67]

Alho HS, Maasilta PK, Harjula AL, et al. Tumor necrosis factor-alpha in a porcine bronchial model of obliterative bronchiolitis[J].Transplantation, 2003, 76(3): 516-523.

基金资助

国家科技重大专项(2023ZD0506305)

AI Summary AI Mindmap
PDF (569KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉